ZymoGenetics has lined up $100 million in fresh financing from Deerfield Management. ZymoGenetics can tap that money in $25 million allotments anytime over the next 18 months. And each tranche will reward Deerfield in a two percent royalty stream from the biotech's Recothrom, a blood-clotting drug. Deerfield will also receive 1.5 million warrants priced at $10.34 on the first draw and a million warrants on each subsequent draw priced at 25 percent above the 15-day average share price. Release